These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 3884114)
1. A double-blind controlled pilot study of plasma exchange versus sham apheresis in chronic progressive multiple sclerosis. Gordon PA; Carroll DJ; Etches WS; Jeffrey V; Marsh L; Morrice BL; Olmstead D; Warren KG Can J Neurol Sci; 1985 Feb; 12(1):39-44. PubMed ID: 3884114 [TBL] [Abstract][Full Text] [Related]
2. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group. Lancet; 1991 Feb; 337(8739):441-6. PubMed ID: 1671468 [TBL] [Abstract][Full Text] [Related]
3. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Weiner HL; Dau PC; Khatri BO; Petajan JH; Birnbaum G; McQuillen MP; Fosburg MT; Feldstein M; Orav EJ Neurology; 1989 Sep; 39(9):1143-9. PubMed ID: 2549450 [TBL] [Abstract][Full Text] [Related]
4. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Noseworthy JH; Ebers GC; Vandervoort MK; Farquhar RE; Yetisir E; Roberts R Neurology; 1994 Jan; 44(1):16-20. PubMed ID: 8290055 [TBL] [Abstract][Full Text] [Related]
5. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. Hauser SL; Dawson DM; Lehrich JR; Beal MF; Kevy SV; Propper RD; Mills JA; Weiner HL N Engl J Med; 1983 Jan; 308(4):173-80. PubMed ID: 6294517 [TBL] [Abstract][Full Text] [Related]
12. Immunoadsorption (IA) versus plasma exchange (PE) in multiple sclerosis--first results of a double blind controlled trial. Schmitt E; Behm E; Buddenhagen F; Ernst B; Hitzschke B; Kracht M; Korten G; Kundt G; Meyer-Rienecker H; Osten B Prog Clin Biol Res; 1990; 337():289-92. PubMed ID: 2191322 [No Abstract] [Full Text] [Related]
13. Immunological treatment of multiple sclerosis. II. Hughes RA J Neurol; 1986 Apr; 233(2):66-8. PubMed ID: 3009722 [No Abstract] [Full Text] [Related]
14. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Cole E; Cattran D; Magil A; Greenwood C; Churchill D; Sutton D; Clark W; Morrin P; Posen G; Bernstein K Am J Kidney Dis; 1992 Sep; 20(3):261-9. PubMed ID: 1519607 [TBL] [Abstract][Full Text] [Related]
15. Mitoxantrone: a review of its use in multiple sclerosis. Scott LJ; Figgitt DP CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110 [TBL] [Abstract][Full Text] [Related]
16. The Mayo Clinic experience with plasma exchange in chronic inflammatory-demyelinating polyneuropathy (CIDP). Dyck PJ; Pineda A; Swanson C; Low P; Windebank A; Daube J Prog Clin Biol Res; 1982; 106():197-204. PubMed ID: 6757940 [TBL] [Abstract][Full Text] [Related]
17. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. 1994 [classical article]. Noseworthy JH; Ebers GC; Vandervoort MK; Farquhar RE; Yetisir E; Roberts R Neurology; 2001 Dec; 57(12 Suppl 5):S31-5. PubMed ID: 11902593 [No Abstract] [Full Text] [Related]